We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gleevec Patients See Almost 90 Percent Survival Rate After Five Years
Gleevec Patients See Almost 90 Percent Survival Rate After Five Years
June 7, 2006
Almost 90 percent of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) were alive five years after they began receiving Gleevec (imatinib), drugmaker Novartis announced at the 2006 annual meeting of the American Society of Clinical Oncology on June 3.